Analysts Set MacroGenics, Inc. (NASDAQ:MGNX) PT at $7.63

MacroGenics, Inc. (NASDAQ:MGNX) has been given an average recommendation of “Hold” by the eleven research firms that are currently covering the stock, MarketBeat.com reports. Eight equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $7.63.

Several research analysts have recently commented on MGNX shares. StockNews.com upgraded MacroGenics from a “sell” rating to a “buy” rating in a report on Sunday, November 10th. JMP Securities lowered shares of MacroGenics from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 7th. Finally, HC Wainwright reissued a “neutral” rating and set a $4.00 target price on shares of MacroGenics in a research note on Wednesday, November 6th.

MacroGenics Stock Performance

NASDAQ:MGNX opened at $2.98 on Monday. The company has a fifty day moving average of $3.25 and a two-hundred day moving average of $3.55. MacroGenics has a fifty-two week low of $2.79 and a fifty-two week high of $21.88. The stock has a market capitalization of $187.03 million, a PE ratio of -1.89 and a beta of 2.02.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd acquired a new position in MacroGenics in the 3rd quarter valued at about $37,000. China Universal Asset Management Co. Ltd. raised its holdings in MacroGenics by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,064 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 4,707 shares during the last quarter. Sanders Morris Harris LLC purchased a new position in shares of MacroGenics during the 4th quarter worth $40,000. SG Americas Securities LLC acquired a new stake in shares of MacroGenics during the third quarter worth $55,000. Finally, XML Financial LLC grew its position in shares of MacroGenics by 66.0% in the third quarter. XML Financial LLC now owns 17,600 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 7,000 shares during the period. Institutional investors and hedge funds own 96.89% of the company’s stock.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.